DIAGNOSIS OF PARKINSON'S DISEASE BY BIOMEDICAL IMAGING METHODS ON THE EXAMPLE OF A CLINICAL CASE

DOI: https://doi.org/10.29296/25877305-2023-10-07
Issue: 
10
Year: 
2023

Associate Professor V. Ryazanov(1), MD; V. Kutsenko(1), Candidate of Medical Sciences; R. Postanogov(1), Associate Professor P. Seliverstov(2, 3), Candidate
of Medical Sciences; M. Gafiatulin(1),
1-Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
2-V.A. Almazov National Medical Research Center, Saint Petersburg
3-S.M. Kirov Military Medical Academy, Saint Petersburg

Worldwide, Parkinson's disease (PD; primary Parkinsonism) is ahead of other neurological disorders in terms of the growth rate of disability and mortality. Despite significant progress in the study of the etiopathogenesis of PD, early diagnosis is a difficult clinical task. The long latent phase of the disease and the absence of reliable laboratory markers often cause a delay in diagnostic neuroimaging, which, together with the potential unwillingness of the radiologist to see changes characteristic of the neurodegenerative process, leads to untimely diagnosis and, as a consequence, a delay in the appointment of therapy. This article provides a literary review of generally recognized visualization patterns of the disease in accordance with modern concepts, and also discusses the issues of differential diagnosis of PD with the most common Parkinsonism-plus syndromes. A clinical case of the diagnosis of Parkinson's disease in a 93-year-old patient by structural magnetic resonance imaging is presented.
Keywords: 
parkinsonism
Parkinson's disease
substantia nigra
neuroimaging
magnetic resonance imaging.

References: 
  1. Pringsheim T., Jette N., Frolkis A et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014; 29: 1583–90. DOI: 10.1002/mds.25945
  2. Grimes D., Fitzpatrick M., Gordon J. et al. Canadian guideline for Parkinson disease. CMAJ. 2019; 191 (36): E989-E1004. DOI: 10.1503/cmaj.181504
  3. Parkinson’s disease in adults. National Institute for Health and Care Excellence. URL: https://www.nice.org.uk/guidance/ng71
  4. Клинические рекомендации. Неврология: Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Ред. совет: Всероссийское общество неврологов, Ассоциация нейрохирургов России. М.: ГЭОТАР-Медиа, 2021 [Klinicheskie rekomendatsii. Nevrologiya: Bolezn' Parkinsona, vtorichnyi parkinsonizm i drugie zabolevaniya, proyavlyayushchiesya sindromom parkinsonizma. Red. sovet: Vserossiiskoe obshchestvo nevrologov, Assotsiatsiya neirokhirurgov Rossii. M.: GEOTAR-Media, 2021 (in Russ.)].
  5. Dickson D/W. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018; 46 (Suppl. 1) S30-S33. DOI: 10.1016/j.parkreldis.2017.07.033
  6. Ward R.J., Zucca F.A., Duyn J.H. et al The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014; 13 (10): 1045–60. DOI: 10.1016/S1474-4422(14)70117-6
  7. Damier P., Hirsch E.C., Agid Y. et al The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 1999; 122: 1421–36. DOI: 10.1093/brain/122.8.1421
  8. Lehéricy S., Bardinet E., Poupon C. et al. 7 Tesla magnetic resonance imaging. A closer look at substantia nigra anatomy in Parkinson’s disease. Mov Disord. 2014; 29: 1574–81. DOI: 10.1002/mds.26043
  9. Reiter E., Mueller C., Pinter B. et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord. 2015; 30: 1068–76. DOI: 10.1002/mds.26171
  10. Schwarz S.T., Xing Y., Tomar P. et al. In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology. 2017; 283 (3): 789–98. DOI: 10.1148/radiol.2016160662
  11. Bae Y.J., Kim J.-M., Sohn C.-H. et al. Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes. Radiology. 2021; 300 (2): 260–78. DOI: 10.1148/radiol.2021203341
  12. Meijer F.J.A., Goraj B., Bloemc B.R. et al. Clinical application of brain MRI in the diagnostic work-up of parkinsonism. J Parkinsons Dis. 2017; 7: 211–7. DOI: 10.3233/JPD-150733
  13. Осборн А.Г., Зальцман К.Л., Завери М.Д. Лучевая диагностика. Головной мозг. 3-е изд. Пер. с англ. М.: Издательство Панфилова, 2018; 1194 с. [Osborn A.G., Salzman K.L., Jhaveri M.D. et al. Diagnostic Imaging. Brain. 3rd ed. Transl. from English. M.: Izdatel'stvo Panfilova, 2018; 1194 p. (in Russ.)].
  14. Öz G., Tkáč I. Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical proofing at 4 T: validation in the cerebellum and brainstem. Magn Reson Med. 2011; 65 (4): 901–10. DOI: 10.1002/mrm.22708
  15. Tan W.Q., Yeoh C.S., Rumpel H. et al. Deterministic Tractography of the Nigrostriatal-Nigropallidal Pathway in Parkinson’s Disease. Sci Rep. 2015; 5: 17283. DOI: 10.1038/srep17283
  16. Kenneth N.J., Chen B., Tomas M.B. et al. Interpreting 123I-ioflupane dopamine transporter scans using hybrid scores. Eur J Hybrid Imaging. 2018; 2 (1): 10. DOI: 10.1186/s41824-018-0028-0
  17. Iwabuchi Y., Kameyam, M., Matsusaka Y. et al. A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis. Eur J Nucl Med Mol Imaging. 2021; 48: 1833–41. DOI: 10.1007/s00259-020-05168-0